Cutaneous adverse events and gemifloxacin: Observations from the clinical trial program

Journal of Chemotherapy

Volumn 18, Issue 1, 2006, Pages 3-11

  Iannini, P ^a   Mandell, L ^b   Patou, G ^c   Shear, N ^d  

^a DANBURY HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c GENOME THERAPEUTICS CORPORATION   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cutaneous adverse reaction; Fluoroquinolone; Gemifloxacin; Rash

Indexed keywords

CALAMINE; CINOXACIN; CIPROFLOXACIN; COMPLEMENT COMPONENT C3; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; IMMUNOGLOBULIN M; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

AGE DISTRIBUTION; ANGIONEUROTIC EDEMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; COMPLEMENT DEPOSITION; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG WITHDRAWAL; FACE EDEMA; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE INFECTION; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; MACULOPAPULAR RASH; NAUSEA; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; RISK FACTOR; SEX RATIO; SINUSITIS; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TASTE DISORDER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URINARY TRACT INFECTION; URTICARIA; VOMITING;

EID: 33645099613     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.1.3     Document Type: Review

References (22)

1. Ball P, Tillotson GS. Fluoroquinolone safety profiles - a comparison of current agents. Today's Therapeutic Trends, 2003; 22: 419-435.
2. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis 1999; 28: 352-364.
3. Ball P, Mandell L, Niki Y, Tillotson GS. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999; 21: 407-421.
4. rd ed. Am Soc Microbiol; Washington DC, USA: Ed Hooper DC & Rubinstein E. 2004: Chapter 28.
5. Martinez LJ, Sik RH, Chignell CF. Fluoroquinolone antibacterials: singlet oxygen, superoxide and phototoxicity. Photochem Photobiol 1999; 67: 399-403
6. Factive product information (gemifloxacin mesylate) (Oscient Pharmaceuticals, Waltham, MA, USA), July 2003.
7. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes (068 Study Group). Clin Ther 2002; 24(4): 639-52.
8. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 2004; 98(8): 697-707.
9. Ball P, Mandell, L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob 2004; Ag; 23: 421-429.
10. Avelox product information (moxifloxacin hydrochloride) (Bayer Corporation, West Haven, CT, USA), 2004.
11. Tequin product information (gatifloxacin) (Bristol Myers Squibb, Princeton, NJ, USA), 2004.
12. Levaquin product information (levofloxacin) (Ortho-McNeil Corporation, Rahway, NJ, USA), 2004.
13. Bigby M. March 2003 at http://www.fda.gov/ohrms/dockets/ac/03/slides/ 3931S1_04_LFLife%20Sciences-Factive.pdf.
14. Ball P. Toxicity of sulphonamide-diaminopyrimidine combinations: implications for future use. J Antimicrob Chemother 1986; 17: 694-696.
15. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; Sep 12; 91(3A): 40S-45S.
16. http://www.bms.com/cgi-bin/anybin.pl?sql=select% 20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_S EQ=97&kev=PPI%22%20target= %22_blank%22%3E): accessed June 2005.
17. http://www.univgraph.com/bayer/inserts/Avelox.pdf: accessed June 2005.
18. Adelglass J, Bundy JM, Woods R. Efficacy and tolerability of cefprozil versus amoxicillin/clavulanate for the treatment of adults with severe sinusitis. Clin Ther 1998; 20(6): 1115-29.
19. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-846.
20. Kubota K, Kubota N, Pearce GL, et al. Signalling drug-induced rash with 36 drugs recently marketed in the United Kingdom and studied by Prescription Event Monitoring. Int J Clin Pharmacol Ther 1995; 33: 219-225.
21. Fogarty C, Zervos M, Tellier G et al. Telithromycin for the treatment of acute exacerbations of chronic bronchitis. Int J Clin Prac 2005; 59: 296-305.
22. Oscient Pharmaceuticals Completes Nationwide FACTIVE Sales Force Expansion -250 territory managers and 25 district managers drive commercialization of FACTIVE. Oscient Pharmaceuticals Press Release, March 18, 2005 (investors.oscient.com); http://investors.oscient.com/phoenix. zhtml?c=97238&p=irol-newsArticle&ID=686906&highlight